Working with its Directors and Advisors including some of the world's leading experts in glaucoma and retinal disease, Galimedix has developed optimized clinical study designs for cost effective and Phase 2 proof of concept in both indications, offering multiple milestones in the near term pointing to a path to product registration.

Alexander Gebauer, M.D., Ph.D.

Co-founder, Executive Chairman

Dr. Gebauer has more than 25 years industry experience in research and development, which led to numerous approvals worldwide in several therapeutic areas. He also holds the positions of managing director and CDO of Omeicos Therapeutics, a Berlin-based biotech company. Before that, he served in several R&D roles, including managing director, president of Global R&D, chief scientific officer and other positions at several international pharmaceutical companies including Sun Pharmaceuticals, Ranbaxy Laboratories, Ltd., Merz Pharmaceuticals, Hoechst AG, Aventis and Sanofi. Dr. Gebauer studied medicine at Johannes Gutenberg University, Mainz, Germany, where he completed his thesis in pharmacology. During his time at Merz, he served as senior vice president, head of Global Research & Development and was directly involved in the development programs of GAL-101 and GAL-201.

Andrew Pearlman, Ph.D.

Founder, President, Board Member

Dr. Andrew Pearlman has more than 35 years’ experience founding and managing US/Israel biotechnology and medical device companies. A biophysicist, Dr. Pearlman has invented, licensed, developed and managed medical devices and biotechnologies from business and product concept through technology development, IP, prototyping, clinical trials, regulatory approval, manufacturing, and product sales. Dr. Pearlman has raised more than $120mm for new biomedical ventures he founded in Israel, including Medgenics, a gene therapy company he took from laboratory research stage through Phase 2 clinical trials and through IPOs on both the London Stock Exchange and the NYSE, building it to over $350 million in market cap. In less than one year, Dr. Pearlman founded Galimedix, built a world class team, and successfully completed a seed round of financing. Dr. Pearlman holds a Ph.D. in Biophysics from the University of California at Berkley (doctoral thesis under Nobel Laureates - Professors Melvin Calvin and Donald Glaser).

Jeffrey Liebmann, M.D.

Board Member

Professor of Ophthalmology, Glaucoma Service Director, and Vice-Chair for the Department of Ophthalmology at Columbia University Medical Center.

Dr. Liebmann graduated from Boston University’s Combined Six-Year Medical Education Program in 1983, completed his ophthalmology residency at the State University of New York/Downstate Medical Center, and glaucoma fellowship training at the New York Eye and Ear Infirmary. Dr. Liebmann was previously Clinical Professor of Ophthalmology at New York University School of Medicine and Director of Glaucoma Services at Manhattan Eye, Ear, and Throat Hospital and New York University Langone Medical Center. Dr. Liebmann currently serves as President of the World Glaucoma Association, past-President of the American Glaucoma Society, Secretary-Treasurer of the New York Glaucoma Society, and co-editor of Journal of Glaucoma and is a member of the Board of Governors of the World Glaucoma Association and Boards of Directors of The Glaucoma Foundation and the American Glaucoma Society Foundation.

In addition to having one of the nation’s busiest tertiary-care glaucoma practices, Dr. Liebmann is also the Principal Investigator of the African Descent and Glaucoma Evaluation Study and is the author and/or co-author of more than 1,000 medical and scientific papers, book chapters, and abstracts. He has lectured widely in the United States and abroad on glaucoma diagnosis and management. His current main areas of research interest include the causes of glaucoma, glaucoma progression, glaucoma surgery, ocular imaging, and neuroprotection.

Thomas C. Hohman, Ph.D.

Board Member

Dr. Thomas Hohman earned his Ph.D. at the University of California at Los Angeles and completed fellowships at the National Heart Blood and Lung Institute, and the National Eye Institute, National Institutes of Health, before beginning his career in drug development. At Wyeth-Ayerst, Dr. Hohman led the aldose reductase inhibitor discovery program, advancing minalrestat into a clinical proof-of-concept (POC) study and establishing a GLP laboratory for quantifying clinical biomarkers for the long-term complications of diabetes. At Novartis Dr. Hohman was the clinical lead for the development of ranibizumab as a treatment for exudative AMD and diabetic macular edema (DME). As the Retina Therapeutic Area Head at Alcon, Dr. Hohman managed the development and clinical evaluation of a VEGFR2 tyrosine kinase inhibitor as a treatment for diabetic macular edema, designed a natural history study of geographic atrophy (GA) and used the data from this study to gain FDA, EMA and PMDA acceptance of atrophic lesion growth as a primary endpoint in studies of new therapeutics for GA; using this endpoint Dr. Hohman evaluated a topically delivered serotonin 1A agonist as a potential treatment for geographic atrophy. As Vice President of Retina Translational Medicine and Head of Retina Drug Discovery at Allergan, Dr. Hohman continued his studies of GA, managing a POC study and a multicenter Phase 2 study of a sustained-release formulation of brimonidine. In a parallel program Dr. Hohman advanced a new biologics platform, designed ankyrin repeat proteins (DARPin) as a treatment for exudative age-related macular degeneration and led discovery efforts of complement inhibitors, as well as bi- and tri-specific DARPins, as the next generation of treatments for exudative AMD and diabetic retinopathy.

Following his retirement, Dr. Hohman has continued his efforts to discover and develop new therapeutics by serving as a consultant to large and small pharmaceutical companies, as well as academicians engaged in the development of therapeutics to address unmet medical needs.

Richel Liu, MS

Board Member

Founder and CEO of Rimonci Capital,she is a member of the fund investment committee. She is responsible for Rimonci overall strategies and transactions control. Prior to founding Rimonci at start of 2016, Richel served as CEO of a comprehensive IT group in China with 1.5 billion USD in sales, and was also Executive Director of a Hong Kong listed company and chairman of a Shanghai listed company in this group. During her tenure, Richel was responsible for various business investments and operations, especially electronics, IC substrate, enterprise software, system integration and finally the overall management of the whole group. With more than 17 years of investment, mergers and acquisitions, business operation and management experience, she has a distinguished track record in setting up new businesses and growing businesses from earlier stage to mature stage either by organic growth or through investment. Richel also has cross-border experience, and in board governance, structure and management. Ms. Liu earned a MS degree in economics and BS degree in engineering. She also received Senior Leadership Training Certification from Yale School of Management. She is a member of Singapore National Eye Center Ophthalmic Technologies Incubator Venture Capital advisory panel.

Cary Sucoff, Esq.

Board Member

Over 30 years of securities industry experience. Owns and operates Equity Source Partners, LLC, an advisory and consulting firm. Participated in financing hundreds of public and private companies, including biotech companies such as Amgen, Genzyme, Genentech, Icos, PathoGenesis, Contrafect, Medgenics and Galimedix. Boards of Directors for Contrafect Corp. (CFRX; Audit/Non-Gov), Galimedix Therapeutics, Inc. (Audit/Non-Gov), First Wave Technologies, Inc. and Legacy Education Alliance, Inc. (LEAI; Audit/ Non-Gov). Consultant to Sapience Therapeutics. Past President of New England Law, Member of the Board of Trustees for over 25 years and Chairman of the Endowment Committee. Member of the Bar of the State of New York (since 1978). BA from SUNY Binghamton and JD from New England School of Law (Managing Editor of the Law Review, graduated Magna Cum Laude).

Phyllis K. Bellin, M.B.A.

Board Member, Chief Financial Officer

Ms. Bellin has more than 30 years' experience in founding and leading technology-based companies. Before joining Galimedix, she served as Vice President Finance & Administration, Corporate Secretary and Treasurer at Medgenics, Inc., leading IPOs on the London AIM and the NYSE. Previously, she was an officer at Citibank in Corporate Lending and Strategic Planning. Since moving to Israel in 1980, Ms. Bellin managed finance and administration for a number of early stage high-tech ventures in automotive safety, and health care. She was also Founder and Vice President of Gintec Active Safety Limited and responsible for finance and administration of its subsidiaries including RoadEye Limited. She served on the Board of Directors of the Misgav Economic Corporation and private companies in Israel and the Netherlands. Ms. Bellin earned her MBA in Finance and Accounting from Columbia University, an MAT from the University of Chicago and a BA from Clark University.

Hermann Russ, M.D. Ph.D.

Co-Founder, Chief Scientific Officer, Board Member

Hermann Russ is a board-certified clinical neurologist, a board-certified experimental pharmacologist and a pharmacist. He is a co-founder of Galimedix. Dr. Russ is the inventor of the use of former Alzheimer-targeting molecule GAL-101 (MRZ-99030) in the treatment of degenerative diseases in the retina including glaucoma and dry macular degeneration. He is also co-inventor of the so-called "trigger effect" of GAL-101 and GAL 201, which is a unique reverse prion-like self-propagation mechanism of action important for the clinical treatment regimen. Dr. Russ championed these assets when they were being developed by Merz beginning in 2007.

He holds a Ph.D. in neuro- and bio-chemistry from the University of Wurzburg, Germany. During his academic career (until 1999) at the universities of Wurzburg, Regensburg and Giessen he had different positions and functions including consultant of clinical neurology and professor of pharmacology. His scientific focus is on neurodegenerative diseases, including Alzheimer's, Parkinson`s, and degenerative retina diseases. He is (co)inventor of around 25 patents and (co)authors of around 50 peer-reviewed scientific publications.

Dr. Russ has 20 years of Pharma industry experience. Prior to joining Galimedix he was vice president of Neuroscience Project Leadership in Specialty R&D of Teva Pharmaceuticals International GmbH (TPIG) Switzerland. His responsibilities included the strategic leadership and management of "project champions" of all global cross-functional drug development programs in the area CNS and pain throughout all phases. He also served on the Swiss Board of TPIG as Managing Officer. Prior to that he worked for 8 years at Merz Pharma as Head of Global R&D CNS leading a R&D organization in the indication areas neurology and psychiatry, spanning from early discovery to clinical development and regulatory submission. That included management of five R&D departments. From 1999 to 2007 Dr. Russ was with Merck KGaA as Head of the Medical Center of Excellence CNS (last position).